SS
FULC icon

Steve Schonfeld’s Fulcrum Therapeutics FULC Stock Holding History

Steve Schonfeld’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.8K Buy
+16,078
New +$97.8K ﹤0.01% 2367
2026
Q1 		– Sell
-16,791
Closed -$190K – 2378
2025
Q4 		$190K Sell
16,791
-349,512
-95% -$3.56M ﹤0.01% 1726
2025
Q3 		$3.37M Buy
366,303
+161,903
+79% +$1.17M 0.02% 777
2025
Q2 		$1.41M Buy
+204,400
New +$1.09M 0.01% 1163
2024
Q2 		– Sell
-29,169
Closed -$275K – 2296
2024
Q1 		$275K Sell
29,169
-403,364
-93% -$3.6M ﹤0.01% 1682
2023
Q4 		$2.92M Buy
+432,533
New +$1.92M 0.02% 678
2023
Q1 		– Sell
-106,600
Closed -$776K – 2273
2022
Q4 		$776K Buy
106,600
+40,000
+60% +$261K 0.01% 1283
2022
Q3 		$539K Buy
66,600
+36,000
+118% +$258K ﹤0.01% 1697
2022
Q2 		$150K Sell
30,600
-9,000
-23% -$88K ﹤0.01% 2007
2022
Q1 		$936K Buy
39,600
+4,100
+12% +$58K 0.01% 1028
2021
Q4 		$628K Sell
35,500
-46,600
-57% -$923K 0.01% 1152
2021
Q3 		$2.32M Buy
+82,100
New +$1.56M 0.02% 667

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steve Schonfeld's FULC Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 16,078 shares worth $58.8K. The stake represents ﹤0.01% of the portfolio and ranks #2367 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in FULC as recently as Q4 2025.

Steve Schonfeld first reported a position in FULC in Q3 2021 and has held it in 12 quarters since. The position peaked at $3.37M in Q3 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Steve Schonfeld held 16,078 shares of Fulcrum Therapeutics worth $58.8K as of Q2 2026.
  • Fulcrum Therapeutics was a new Steve Schonfeld position in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #2367 holding.
  • Steve Schonfeld first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Steve Schonfeld's Fulcrum Therapeutics position peaked at $3.37M in Q3 2025.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.